VISUS THERAPEUTICS

Visus Therapeutics Initiates Phase 3 Pivotal Trials of BRIMOCHOL™ PF for the Treatment of Presbyopia

Retrieved on: 
Tuesday, March 22, 2022
Biotechnology, Health, Pharmaceutical, Optical, Clinical Trials, Pupil, Therapy, LinkedIn, Smartphone, BRIO, Glaucoma, Research, Wound healing, Reading, Brimonidine, Retina, Carbachol, Prevalence, American Academy of Optometry, Safety, Reduction, Presbyopia, Time, Ageing, Clinical study design, American Academy, Hardship, Visu, McLaurin, Eye, Instagram, Insurance, Patient, Pharmaceutical industry, Telescopic sight, Optometry, New Drug Application, Twitter, PRESBYOPIA, VISUS THERAPEUTICS

The initiation of the BRIO trials follows compelling topline data from the companys Phase 2 VIVID clinical study, which demonstrated two preservative-free formulations, BRIMOCHOL PF and Carbachol PF, were well tolerated and met clinical outcomes to support advancement into pivotal trials.

Key Points: 
  • The initiation of the BRIO trials follows compelling topline data from the companys Phase 2 VIVID clinical study, which demonstrated two preservative-free formulations, BRIMOCHOL PF and Carbachol PF, were well tolerated and met clinical outcomes to support advancement into pivotal trials.
  • The initiation of our first Phase 3 trial is a momentous occasion for Visus Therapeutics.
  • The BRIO-I and BRIO-II trials are designed to study BRIMOCHOL PF, a novel, fixed-dose combination of carbachol and brimonidine tartrate, and a proprietary, preservative-free formulation of carbachol monotherapy.
  • In parallel, Visus Therapeutics is focused on advancing its pipeline of early-stage ophthalmic drug candidates with applications in corneal wound healing, glaucoma and age-related macular degeneration.

Visus Therapeutics Announces Positive Topline Clinical Data from Phase 2 VIVID Study of BRIMOCHOL for the Treatment of Presbyopia

Retrieved on: 
Tuesday, November 30, 2021
Professional Services, Health, Venture Capital, Clinical Trials, Pharmaceutical, Optical, Biotechnology, Patient, Visu, Visual acuity, Ageing, Safety, Population, Lens (anatomy), Headache, VIVID, Brimonidine, Presbyopia, Research, NYU, Instagram, FDA, Glaucoma, Iraj Zebardast, Therapy, LinkedIn, Prevalence, Toxicity, Quality of life, Pharmaceutical industry, Presbyopia, Visus Therapeutics, PRESBYOPIA, VISUS THERAPEUTICS

A minimum of 35% of subjects in the study met this same endpoint at nine hours in all three formulations.

Key Points: 
  • A minimum of 35% of subjects in the study met this same endpoint at nine hours in all three formulations.
  • Based on these positive outcomes, the company plans to commence Phase 3 pivotal trials shortly.
  • The successful completion of the VIVID study marks an important milestone for Visus Therapeutics, said Ben Bergo, co-founder and chief executive officer at Visus Therapeutics.
  • We are pleased the VIVID study data exceeded our expectations, demonstrating a clear opportunity to commercialize long-acting miotic formulations.

Visus Therapeutics Hosts Inaugural Capital Markets Day in New York City

Retrieved on: 
Tuesday, September 14, 2021
Clinical Trials, Professional Services, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Optical, Other Professional Services, BRIMOCHOL, Visus Therapeutics, BRIMOCHOL, VISUS THERAPEUTICS

Visus Therapeutics Inc., a clinical-stage pharmaceutical company focused on developing innovative ophthalmic therapies to improve vision for people around the world, recently welcomed investors, analysts and media to its inaugural Capital Markets Day in New York City.

Key Points: 
  • Visus Therapeutics Inc., a clinical-stage pharmaceutical company focused on developing innovative ophthalmic therapies to improve vision for people around the world, recently welcomed investors, analysts and media to its inaugural Capital Markets Day in New York City.
  • Visus Therapeutics leadership also unveiled additional ophthalmic drug candidates with applications in development for corneal wound healing, glaucoma and age-related macular degeneration (AMD).
  • Visus Therapeutics is a clinical-stage pharmaceutical company focused on developing innovative ophthalmic therapies to improve vision for people around the world.
  • The video of the presentations from the Visus Therapeutics Capital Markets Day is available here on the Visus Therapeutics web site.

 Visus Therapeutics Appoints Industry Leaders Tracy Valorie and Dwight Moxie to Board of Directors

Retrieved on: 
Wednesday, August 25, 2021
Other Professional Services, Biotechnology, Pharmaceutical, Optical, General Health, Health, Professional Services, Other Health, General manager, General counsel, Company, Glaucoma, Howard University School of Law, Fifth Avenue, Florida State University, MS, Ophthalmic, University, Allergan, Ophthalmology, Instagram, Presbyopia, Learning Technology Partners, Rensselaer Polytechnic Institute, Board of directors, Research, Optometry, Corporation, Therapy, Marketing, Pfizer, Senior, MBA, Molecular biology, Board, MHSA, GlaxoSmithKline, Visu, LinkedIn, Compliance, Law, Bausch & Lomb, Bausch, News, Capital market, MD, Management, Pharmaceutical industry, Tracy Valorie, Dwight Moxie, Visus Therapeutics, TRACY VALORIE, DWIGHT MOXIE, VISUS THERAPEUTICS

I am very pleased to welcome Tracy Valorie and Dwight Moxie to Visus Therapeutics Board of Directors, said Ben Bergo, co-founder and chief executive officer at Visus Therapeutics.

Key Points: 
  • I am very pleased to welcome Tracy Valorie and Dwight Moxie to Visus Therapeutics Board of Directors, said Ben Bergo, co-founder and chief executive officer at Visus Therapeutics.
  • Ms. Valorie previously served as Senior Vice President and General Manager of US Ophthalmology Rx and Surgical at Bausch + Lomb.
  • I am honored to join Visus Therapeutics Board of Directors and am looking forward to working with this talented and capable team, said Tracy Valorie.
  • Dwight Moxie is the General Counsel, Senior Vice President and Corporate Secretary at Revance Therapeutics.

Visus Therapeutics Secures $20 Million in Additional Financing Led by New Investor LSP, with Participation from Sage Partners

Retrieved on: 
Tuesday, August 10, 2021
Professional Services, Health, Venture Capital, General Health, Pharmaceutical, Optical, Biotechnology, FDA, Patient, Carbachol, Presbyopia, Knowledge, LSP, Bergo, American Optometric Association, Drug development, Industry, LinkedIn, Therapy, Instagram, Ageing, General partnership, Board, Capital market, Company, Pharmaceutical industry, Presbyopia, Visus Therapeutics, PRESBYOPIA, VISUS THERAPEUTICS

In conjunction with this financing, John de Koning, Ph.D., a General Partner at LSP, has joined the Companys Board of Directors.

Key Points: 
  • In conjunction with this financing, John de Koning, Ph.D., a General Partner at LSP, has joined the Companys Board of Directors.
  • BRIMOCHOL is an investigational drug designed to be a once-daily eye drop to correct for the loss of near vision associated with presbyopia.
  • Im looking forward to partnering with my fellow board members and the entire Visus Therapeutics management team to deliver BRIMOCHOL and other exciting ophthalmic therapeutics to patients.
  • Visus Therapeutics is a clinical-stage company focused on developing innovative ophthalmic therapies to improve vision for people around the world.